Skip to main content Skip to main content
Go to homepage

Ferimoxytol vs. Iron Sucrose

Ferimoxytol vs. Iron Sucrose in Pediatric Anemia Patients


To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric chronic kidney disease (CKD) subjects with iron deficiency anemia (IDA) or who are at risk of development of IDA.

For complete study information please visit

Who May Qualify?:
  1. Male or female 2 years to <18 years of age at time of consent
  2. Has IDA defined as: a) hemoglobin <12.0 g/dL and b) with either transferrin saturation (TSAT) <40% or ferritin <100 ng/mL; or considered to be at risk of development of IDA, i.e., TSAT<20% with falling hemoglobin during the preceding 2 months and a history of hemoglobin <12 g/dL
  3. Has Chronic Kidney Disease defined as one of the following:
    • on chronic hemodialysis;
    • receiving chronic peritoneal dialysis;
    • estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m2;
    • has evidence of structural and/or functional abnormalities e.g., persistent albuminuria, abnormal urine sediment, electrolyte and other abnormalities due to tubular disorders for > 3 months.
  4. For patients other than hemodialysis dependent CKD patients, documented history of unsatisfactory oral iron therapy or in whom oral iron cannot be tolerated, or for whom oral iron is considered medically inappropriate
  5. All subjects (female and male) of childbearing potential who are sexually active must be on an effective method of birth control for at least 1 month prior to Day 1 Dosing and agree to remain on birth control until completion of the study
Who Does Not Qualify:
  1. Known hypersensitivity reaction to any component of ferumoxytol and iron sucrose
  2. History of allergy to intravenous (IV) iron
  3. History of multiple drug allergies (>2)
  4. Low systolic blood pressure (Age 1-9 years <70 + [age in years x 2] mmHg, Age 10-17 years <90 mmHg)
  5. Hemoglobin ≤7.0 g/dL
  6. Serum ferritin level >600 ng/mL
  7. Children younger than 2 or over 17 years
Study Status:
Study Sponsor:

AMAG Pharmaceuticals

Full IRB Study Title:
A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects with Chronic Kidney Disease Protocol No: AMAG-FER-CKD-354
IRB Study ID:
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email
Lead Investigator
Rupesh Raina, MD, FACP, FAAP

Pediatric Nephrologist
Pediatric NephrologyPediatric Hypertension ClinicKidney Stone Clinic

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.